Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. develops investigational medicines as a clinical-stage TechBio company using the Recursion OS, an AI-native drug discovery and development platform that integrates biology, chemistry, automation, data science and clinical development. Company updates center on wholly owned and partnered programs in oncology, rare disease, neuroscience, immunology and other therapeutic areas.
Recurring announcements cover clinical and preclinical pipeline progress, financial results, platform infrastructure, automated laboratory operations, collaborations and partner milestones. Recursion also reports governance and leadership changes, investor-conference participation and updates tied to named programs such as REC-1245, REC-4881 and REC-4539 when those programs advance through development.
Recursion (NASDAQ: RXRX) has received regulatory clearances for two key oncology drugs to advance to clinical trials. The UK MHRA cleared a Phase 1 trial for REC-3565, a MALT1 inhibitor targeting B-cell malignancies, with a potential addressable market of 41,000 relapsed/refractory patients with chronic lymphocytic leukemia and B-cell lymphomas in US+EU5 annually.
The FDA cleared an IND application for REC-4539, a reversible and CNS-penetrant LSD1 inhibitor for small-cell lung cancer, targeting approximately 45,000 extensive stage SCLC patients annually in US+EU5. REC-3565 is designed to reduce hyperbilirubinemia risk, while REC-4539 is the first reversible LSD1 inhibitor designed to penetrate the brain.
Recursion (NASDAQ: RXRX), a clinical stage TechBio company, has announced that its co-founder and CEO Chris Gibson, PhD, will deliver a presentation at the 43rd Annual JP Morgan Healthcare Conference in San Francisco. The presentation is scheduled for Monday, January 13, at 7:30am PT (10:30am ET) in the Elizabethan Room A/B at the Westin St. Francis.
Dr. Gibson will provide updates on three key areas: Recursion's clinical pipeline, partnerships, and platform developments following the company's recent merger with Exscientia. The presentation will be accessible on Recursion's investor relations website for a minimum of 30 days after the event.
Iambic Therapeutics has appointed Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer. Dr. Secora, formerly CFO at Recursion (NASDAQ: RXRX), brings extensive experience in technology-driven drug development, combining scientific, capital markets, and business expertise.
At Recursion, he led finance, communications, and investor relations, orchestrating collaborations with major companies like Bayer and Roche-Genentech, and raising over $1.3 billion through private and public funding rounds.
Iambic's pipeline includes IAM1363, a HER2 inhibitor in Phase 1 with data expected in 2025, along with other programs including a dual CDK2/4 inhibitor and an allosteric KIF18A inhibitor. The company's platform integrates chemical synthesis, mass spectrometry, and AI technology, demonstrating ability to advance from program initiation to Phase 1 trials in approximately 2 years.
Recursion Pharmaceuticals (NASDAQ: RXRX) announced the approval of inducement restricted stock unit (RSU) awards by its Board's Compensation Committee on December 19, 2024. The grants cover 7,952,836 shares of class A common stock, distributed among 230 new employees under the company's 2024 Inducement Equity Incentive Plan. These awards were granted in connection with Recursion's acquisition of Exscientia plc. The RSUs will vest quarterly at a rate of 1/16th of shares on February 15, May 15, August 15, and November 15, starting February 15, 2025, contingent on continued employment.
Recursion (RXRX) announced interim Phase 1 clinical data for REC-617, their CDK7 inhibitor, showing promising results in advanced solid tumors. The study included 18 response-evaluable patients with doses ranging from 2mg to 20mg once daily and 1mg twice daily.
Key highlights include a confirmed partial response in a platinum-resistant ovarian cancer patient, ongoing after 6+ months of treatment, and stable disease in four additional patients for up to 6 months. The drug demonstrated favorable tolerability with predominantly Grade 1-2 adverse events and no treatment discontinuations.
REC-617 showed rapid absorption, dose-linear pharmacokinetics, and robust biomarker modulation. The company plans to continue monotherapy dose escalation and initiate combination studies in first half of 2025.
Recursion (NASDAQ: RXRX) has initiated dosing in its Phase 1/2 DAHLIA clinical trial of REC-1245, a novel RBM39 degrader targeting biomarker-enriched solid tumors and lymphoma. The drug, developed using AI-powered biology mapping, moved from target identification to IND studies in under 18 months. REC-1245 works by inducing splicing defects that downregulate DNA Damage Response networks and cell cycle checkpoints, potentially addressing over 100,000 patients in the US and EU5. The DAHLIA trial aims to evaluate safety, tolerability, and preliminary activity, while determining maximum tolerated dose for both single-agent use and combinations with other treatments.
Recursion (RXRX) and Exscientia have completed their business combination, with Exscientia becoming a wholly owned subsidiary of Recursion. The merged entity now features more than 10 clinical and preclinical programs, 10 advanced discovery programs, and over 10 partnered programs. The company has received $450M in upfront and milestone payments to date, with potential for over $20B in additional milestone payments. The combined platform integrates Exscientia's chemical design methods with Recursion's 60+ petabytes of proprietary data. The merged company will employ approximately 800 people, headquartered in Salt Lake City with offices across North America and Europe.
Recursion (RXRX) and Exscientia (EXAI) shareholders have approved their proposed business combination, with the transaction expected to close on November 20, 2024. The combined company will integrate Recursion's biological and chemical exploration capabilities with Exscientia's molecular design and automated chemistry synthesis expertise to enhance drug discovery processes. An update call is scheduled for November 20, 2024, at 7:30 a.m. ET. The final voting results will be disclosed in regulatory filings with the SEC.
Recursion (NASDAQ: RXRX) has released OpenPhenom-S/16, a publicly available foundation model in Google Cloud's Vertex AI Model Garden. The model, trained on over three million microscopy images from public datasets, sets a new performance standard for microscopy data analysis, outperforming traditional methods like CellProfiler. The model enables automated classification of cellular structures and pattern detection without requiring additional tuning. Alongside the model, Recursion is releasing the RxRx3-core dataset, which includes labeled images of 735 genetic knockouts and 1,674 small-molecule perturbations, designed to advance research in drug mechanism mapping.
Recursion (RXRX) reported Q3 2024 financial results with revenue of $26.1 million, up from $10.5 million in Q3 2023. The company achieved multiple clinical milestones, including positive Phase 2 CCM trial data and FDA clearance for a Phase 1/2 trial in biomarker-enriched tumors. Roche-Genentech optioned their first neuroscience phenomap for $30 million. The company expanded its collaboration with Google Cloud for drug discovery platform support. Q3 net loss was $95.8 million with cash position of $427.6 million. The pending business combination with Exscientia is expected to close on November 20, 2024.